Key result
The combination of CRISPR/Cas9 RNP complex and recombinant AAV6 vectors resulted in successful transgene delivery into the AAVS1 safe harbor site of human iPSCs.
Why the study?
Precise transgene insertion in hiPSCs represents a significant challenge because viral transduction causes random integration and non-viral strategies suffer from low transfection efficiency.
The combination of CRISPR/Cas9 RNP complex and recombinant AAV6 vectors enables precise and efficient transgene knock-in at the AAVS1 safe harbor locus in human iPSCs.
Answers are grounded in this paper and cite their sources.
Facilitates precise gene editing in human iPSCs; leaves open clinical translation pending in vivo validation.
Genome editing in human induced pluripotent stem cells (hiPSCs) offers a potential tool for studying gene functions in disease models and correcting genetic mutations for cell-based therapy. Precise transgene insertion in hiPSCs represents a significant challenge. In the past decade, viral transduction has been widely used due to its high transduction efficiency; however, it can result in random transgene integration and variable transgene copy numbers. Non-viral-based strategies are generally safer but limited by their low transfection efficiency in hiPSCs. Recently, genome engineering using adeno-associated virus (AAV) vectors has emerged as a promising gene delivery approach due to AAVs' low immunogenicity, toxicity, and ability to infect a broad range of cells. The following protocol describes the workflow for genome editing in hiPSCs using the CRISPR/Cas9 ribonucleoprotein (RNP) complex combined with the recombinant AAV serotype 6 (AAV6) donor vectors to introduce a gene of interest (GOI) fused with mCherry fluorescent reporter gene into the AAVS1 safe harbor site. This approach leads to efficient transgene insertion and is applicable to precise genome editing of hiPSCs or other types of stem cells for research purposes.
No takes yet. Share an insight, caveat, or question.
Chupradit et al. (2022) studied In vitro human induced pluripotent stem cells (hiPSCs). CRISPR/Cas9 RNP complex combined with recombinant AAV6 donor vectors vs. RNP + pAAV donor plasmid or AAV6 alone was evaluated on Percentage of mCherry+ cells (transgene insertion). The combination of CRISPR/Cas9 RNP complex and recombinant AAV6 vectors resulted in successful transgene delivery into the AAVS1 safe harbor site of human iPSCs.
Synapse has enriched 10 related papers. Consider them for comparative context: